论文部分内容阅读
1992年被批准的26个新分子产品(new molecular entities,NMEs)平均考察时间是29.9个月,比1991年FDA考察通过的30个NMEs平均花30.3个月稍微缩短了一些。批准的26个新药中有4个药:索他洛尔(sotalol)、噁丙秦(oxaprozin)、氨氯地平(amlodipine)和奈多罗米钠(sodium nedocromil)。经4年多的考察方获FDA批准。被授予新的“优先”类的11个药中,4个药是针对HIV或与艾滋病有关疾病的,这是在一年中批准用于治疗该病药物数目最多的一年。这4个药获得批准所用的平均时间为13.4个月。获得批准最快的一个NME是紫
The average number of 26 new molecular entities (NMEs) approved in 1992 was 29.9 months, slightly less than the 30.3 months spent on 30 NMEs approved by the FDA in 1991. Of the 26 approved new drugs, 4 are sotalol, oxaprozin, amlodipine and sodium nedocromil. After 4 years of inspection by the FDA approved. Of the 11 drugs that were awarded the new “priority” category, four were targeted at HIV or AIDS-related illnesses, the largest number approved for the treatment of the disease during the year. The average time taken for approval of the four drugs was 13.4 months. One of the fastest-approved NMEs is purple